BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Van Acker HH, Van Acker ZP, Versteven M, Ponsaerts P, Pende D, Berneman ZN, Anguille S, Van Tendeloo VF, Smits EL. CD56 Homodimerization and Participation in Anti-Tumor Immune Effector Cell Functioning: A Role for Interleukin-15. Cancers (Basel) 2019;11:E1029. [PMID: 31336622 DOI: 10.3390/cancers11071029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Gadgeel M, AlQanber B, Buck S, Taub JW, Ravindranath Y, Savaşan S. Aberrant myelomonocytic CD56 expression in Down syndrome is frequent and not associated with leukemogenesis. Ann Hematol 2021;100:1695-700. [PMID: 33890142 DOI: 10.1007/s00277-021-04531-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Gunesch JT, Dixon AL, Ebrahim TA, Berrien-Elliott MM, Tatineni S, Kumar T, Hegewisch-Solloa E, Fehniger TA, Mace EM. CD56 regulates human NK cell cytotoxicity through Pyk2. Elife 2020;9:e57346. [PMID: 32510326 DOI: 10.7554/eLife.57346] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
3 Gunesch JT, Dixon AL, Ebrahim T, Berrien-elliott M, Tatineni S, Kumar T, Solloa EH, Fehniger TA, Mace EM. CD56 regulates human NK cell cytotoxicity through Pyk2.. [DOI: 10.1101/2020.03.19.998427] [Reference Citation Analysis]